Intramuscular injection of tumor necrosis factor-alpha induces muscle hyperalgesia in rats

Pain

Volumn 104, Issue 3, 2003, Pages 579-588

  Schäfers, Maria ^a,b   Sorkin, Linda S ^b   Sommer, Claudia ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcitonin gene related peptide; Muscle hyperalgesia; Muscle pain; Nerve growth factor; Prostaglandins; Tumor necrosis factor

Indexed keywords

ANALGESIC AGENT; CALCITONIN GENE RELATED PEPTIDE; FORMALDEHYDE; NERVE GROWTH FACTOR; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BICEPS BRACHII MUSCLE; CELL INFILTRATION; CONFERENCE PAPER; CONTROLLED STUDY; EDEMA; FORCE; FORELIMB; GASTROCNEMIUS MUSCLE; GRIP STRENGTH; HISTOPATHOLOGY; HYPERALGESIA; INJECTION; LATENT PERIOD; MACROPHAGE; MECHANICAL STIMULATION; MOTOR DYSFUNCTION; MUSCLE INJURY; MUSCLE TISSUE; MYALGIA; NONHUMAN; PATHOPHYSIOLOGY; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; RAT; THERMAL STIMULATION; TIME; TISSUE INJURY; UPREGULATION; WITHDRAWAL REFLEX; ANIMAL; ARTICLE; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PAIN ASSESSMENT; PATHOLOGY; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT;

ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERALGESIA; INJECTIONS, INTRAMUSCULAR; MUSCLE, SKELETAL; NERVE GROWTH FACTOR; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141955939     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(03)00115-5     Document Type: Conference Paper

References (73)

1. Alvarez B., Quinn L.S., Busquets S., Lopez-Soriano F.J., Argiles J.M. TNF-alpha modulates cytokine and cytokine receptors in C2C12 myotubes. Cancer Lett. 175:2002;181-185.
2. Alvarez B., Quinn L.S., Busquets S., Quiles M.T., Lopez-Soriano F.J., Argiles J.M. Tumor necrosis factor-alpha exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells. Biochim Biophys Acta. 1542:2002;66-72.
3. Arendt-Nielsen L. Induction and assessment of experimental pain from human skin, muscle, and viscera. Jensen T.S., Turner J.A., Wiesenfeld-Hallin Z. Proceedings of the 8th World Congress of Pain. 1997;IASP Press, Seattle.
4. Arendt-Nielsen L., Graven-Nielsen T., Svensson P., Jensen T.S. Temporal summation in muscles and referred pain areas: an experimental human study. Muscle Nerve. 20:1997;1311-1313.
5. Beutler B., Cerami A. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature. 320:1986;584-588.
6. Beutler B.A., Milsark I.W., Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol. 135:1985;3972-3977.
7. Bulling D.G., Kelly D., Bond S., McQueen D.S., Seckl J.R. Adjuvant-induced joint inflammation causes very rapid transcription of beta-preprotachykinin and alpha-CGRP genes in innervating sensory ganglia. J Neurochem. 77:2001;372-382.
8. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 53:1994;55-63.
9. Cunha F., Poole S., Lorenzetti B., Ferreira S. The pivotal role of tumor necrosis factor-alpha in the development of inflammatory hyperalgesia. Br J Pharmacol. 107:1992;660-664.
10. De Bleecker J.L., Meire V.I., Declercq W., Van Aken E.H. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord. 9:1999;239-246.
11. De Rossi M., Bernasconi P., Baggi F., de Waal Malefyt R., Mantegazza R. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol. 12:2000;1329-1335.
12. Dinarello C.A., Cannon J.G., Wolff S.M., Bernheim A., Beutler B., Cerami A., Figari S., Palladino J.R., O'Connor J.V. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med. 163:1986;1433-1450.
13. Dixon W. The up-and-down method for small samples. J Am Statist Assoc. 60:1965;967-978.
14. Dubner R. Hyperalgesia in response to injury to cutaneous and deep tissues. Seattle J., Dubner R. Orofacial pain and temporomandibular disorders. 1995;61-71 Raven Press, New York.
15. Dyck P.J., Peroutka S., Rask C., Burton E., Baker M.K., Lehman K.A., Gillen D.A., Hokanson J.L., O'Brien P.C. Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans. Neurology. 48:1997;501-505.
16. Fam A.G. Recent advances in the management of adult myositis. Expert Opin Investig Drugs. 10:2001;1265-1277.
17. Fedczyna T.O., Lutz J., Pachman L.M. Expression of TNF-alpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNF-alpha 308A allele. Clin Immunol. 100:2001;236-239.
18. George A., Marziniak M., Schäfers M., Toyka K.V., Sommer C. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain. 88:2000;267-275.
19. Graven-Nielsen T., Mense S. The peripheral apparatus of muscle pain: evidence from animal and human studies. Clin J Pain. 17:2001;2-10.
20. Graven-Nielsen T., Arendt-Nielsen L., Svensson P., Jensen T.S. Stimulus-response functions in areas with experimentally induced referred muscle pain - a psychophysical study. Brain Res. 744:1997;121-128.
21. Hastings R.H., Hua X.Y. Expression of calcitonin gene-related peptide by cultured rat alveolar type II cells. Am J Respir Cell Mol Biol. 13:1995;563-569.
22. Hopkins P.M. Human recombinant TNF-alpha affects rat diaphragm muscle in vitro. Intensive Care Med. 22:1996;359-362.
23. Ji R., Samad T., Jin S., Schmoll R., Woolf C. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron. 36:2002;57.
24. Kantor T.G. The pharmacological control of musculoskeletal pain. Can J Physiol Pharmacol. 69:1991;713-718.
25. Keay K.A., Clement C.I., Matar W.M., Heslop D.J., Henderson L.A., Bandler R. Noxious activation of spinal or vagal afferents evokes distinct patterns of fos-like immunoreactivity in the ventrolateral periaqueductal gray of unanaesthetised rats. Brain Res. 948:2002;122-130.
26. Kehl L.J., Trempe T.M., Hargreaves K.M. A new animal model for assessing mechanisms and management of muscle hyperalgesia. Pain. 85:2000;333-343.
27. Kniffki K.D., Mense S., Schmidt R.F. Responses of group IV afferent units from skeletal muscle to stretch, contraction and chemical stimulation. Exp Brain Res. 31:1978;511-522.
28. Kuru S., Inukai A., Liang Y., Doyu M., Takano A., Sobue G. Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol (Berl). 99:2000;585-588.
29. Lepidi H., Frances V., Figarella-Branger D., Bartoli C., Machado-Baeta A., Pellissier J.F. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol. 24:1998;73-79.
30. Lund J.P., Stohler C.S., Widmer C.G. The relationship between pain and muscle activity in fibromyalgia and similar conditions. Vaeroy J., Merskez H. Progress in fibromyalgia and myofascial pain. 1993;Elsevier, Amsterdam.
31. Lundberg I.E. The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep. 2:2000;216-224.
32. Lundberg I., Ulfgren A.K., Nyberg P., Andersson U., Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 40:1997;865-874.
33. Maes M., Libbrecht I., Van Hunsel F., Lin A.H., De Clerck L., Stevens W., Kenis G., de Jongh R., Bosmans E., Neels H. The immune-inflammatory pathophysiology of fibromyalgia: Increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines. Psychoneuroendocrinology. 24:1999;371-383.
34. Maixner W., Sigurdsson A., Fillingim R.B., Lundeen T., Booker D.K. Regulation of acute and chronic orofacial pain. Fricton J., Dubner R. Orofacial pain and temporomandibular disorders. 1995;85-102 Raven Press, New York.
35. McCain G.A. Fibromyalgia and myofascial pain. Wall P.D., Melzack R. Textbook of pain. 1994;475-493 Churchill Livingstone, New York.
36. McMahon S.B. NGF as a mediator of inflammatory pain. Philos Trans R Soc Lond B Biol Sci. 351:1996;431-440.
37. Mense S. Pathophysiology of low back pain and the transition to the chronic state - experimental data and new concepts. Schmerz. 15:2001;413-417.
38. Mense S., Skeppar P. Discharge behaviour of feline gamma-motoneurones following induction of an artificial myositis. Pain. 46:1991;201-210.
39. Molander C., Grant G. Cutaneous projections form the rat hindlimb foot to the substantia gelatinosa of the spinal cord studied by transganglionic transport of WGA-HRP-conjugate. J Comp Neurol. 237:1985;476-484.
40. Molander C., Grant G. Spinal cord projections from hindlimb muscle nerves in the rat studied by transganglionic transport of horseradish peroxidase, wheat germ agglutinin conjugated horseradish peroxidase, or horseradish peroxidase with dimethylsulfoxide. J Comp Neurol. 260:1987;246-255.
41. Molander C., Ygge J., Dalsgaard C.J. Substance P-, somatostatin- and calcitonin gene-related peptide-like immunoreactivity and fluoride resistant acid phosphatase-activity in relation to retrogradely labeled cutaneous, muscular and visceral primary sensory neurons in the rat. Neurosci Lett. 74:1987;37-42.
42. Molin C. Vertical isometric muscle forces of the mandible. A comparative study of subjects with and without manifest mandibular pain dysfunction syndrome. Acta Odontol Scand. 30:1972;485-499.
43. Moller E., Sheikholeslam A., Lous I. Response of elevator activity during mastication to treatment of functional disorders. Scand J Dent Res. 92:1984;64-83.
44. Nordenskiold U.M., Grimby G. Grip force in patients with rheumatoid arthritis and fibromyalgia and in healthy subjects. A study with the Grippit instrument. Scand J Rheumatol. 22:1993;14-19.
45. O'Brien P.C., Woolf C.J., Fitzgerald M., Lindsay R.M., Molander C. Differences in the chemical expression of rat primary afferent neurons which innervate skin, muscle or joint. Neuroscience. 32:1989;493-502.
46. Ohtori S., Takahashi K., Chiba T., Takahashi Y., Yamagata M., Sameda H., Moriya H. Fos expression in the rat brain and spinal cord evoked by noxious stimulation to low back muscle and skin. Spine. 25:2000;2425-2430.
47. Petty B.G., Cornblath D.R., Adornato B.T., Chaudhry V., Flexner C., Wachsman M., Sinicropi D., Burton L.E., Peroutka S.J. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol. 36:1994;244-246.
48. Plenderleith M.B., Snow P.J. The plant lectin Bandeiraea simplicifolia IB4 identifies a subpopulation of small diameter primary sensory neurons which innervate the skin in the rat. Neurosci Lett. 159:1993;17-20.
49. Reid M.B., Li Y.P. Cytokines and oxidative signalling in skeletal muscle. Acta Physiol Scand. 171:2001;225-232.
50. Reid M.B., Lannergren J., Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med. 166:2002;479-484.
51. Roddy E., Courtney P.A., Morris A. Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology (Oxford). 41:2002;1194-1195.
52. Schäfers M., Geis C., Brors D., Yaksh T.L., Sommer C. Anterograde transport of tumor necrosis factor-alpha in the intact and injured rat sciatic nerve. J Neurosci. 22:2002;536-545.
53. Shephard G. Muscle sense and kinesthesia. 1994;Oxford University Press, New York.
54. Shimizu T., Tomita Y., Son K., Nishinarita S., Sawada S., Horie T. Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol. 19:2000;352-359.
55. Shindoh C., Hida W., Ohkawara Y., Yamauchi K., Ohno I., Takishima T., Shirato K. TNF-alpha mRNA expression in diaphragm muscle after endotoxin administration. Am J Respir Crit Care Med. 152:1995;1690-1696.
56. Skyba D.A., King E.W., Sluka K.A. Effects of NMDA and non-NMDA ionotropic glutamate receptor antagonists on the development and maintenance of hyperalgesia induced by repeated intramuscular injection of acidic saline. Pain. 98:2002;69-78.
57. Sluka K.A. Stimulation of deep somatic tissue with capsaicin produces long-lasting mechanical allodynia and heat hypoalgesia that depends on early activation of the cAMP pathway. J Neurosci. 22:2002;5687-5693.
58. Sluka K.A., Kalra A., Moore S.A. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve. 24:2001;37-46.
59. Sluka K.A., Rohlwing J.J., Bussey R.A., Eikenberry S.A., Wilken J.M. Chronic muscle pain induced by repeated acid injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists. J Pharmacol Exp Ther. 302:2002;1146-1150.
60. Stohler C.S. Temporomandibular disorders and related pain conditions. Sessle B.J., Bryant P.S., Dionee R.A. Progress in pain research and management. 1995;3-30 Elsevier, Amsterdam.
61. Stohler C.S., Kowalski C.J., Lund J.P. Muscle pain inhibits cutaneous touch perception. Pain. 92:2001;327-333.
62. Susaki Y., Shimizu S., Katakura K., Watanabe N., Kawamoto K., Matsumoto M., Tsudzuki M., Furusaka T., Kitamura Y., Matsuda H. Functional properties of murine macrophages promoted by nerve growth factor. Blood. 15:1996;4630-4637.
63. Svensson P., Graven-Nielsen T., Arendt-Nielsen L. Mechanical hyperesthesia of human facial skin induced by tonic painful stimulation of jaw muscles. Pain. 74:1998;93-100.
64. Tews D.S., Goebel H.H. Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol. 55:1996;342-347.
65. Wallace D.J., Linker-Israeli M., Hallegua D., Silverman S., Silver D., Weisman M.H. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford). 40:2001;743-749.
66. Wilcox P., Osborne S., Bressler B. Monocyte inflammatory mediators impair in vitro hamster diaphragm contractility. Am Rev Respir Dis. 146:1992;462-466.
67. Wilcox P.G., Wakai Y., Walley K.R., Cooper D.J., Road J. Tumor necrosis factor-alpha decreases in vivo diaphragm contractility in dogs. Am J Respir Crit Care Med. 150:1994;1368-1373.
68. Wilcox P., Milliken C., Bressler B. High-dose tumor necrosis factor-alpha produces an impairment of hamster diaphragm contractility. Attenuation with a prostaglandin inhibitor. Am J Respir Crit Care Med. 153:1996;1611-1615.
69. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L. The American College of Rheumatology criteria of the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum. 33:1990;160-172.
70. Woolf C.J. Phenotypic modification of primary sensory neurons: the role of nerve growth factor in the production of persistent pain. Philos Trans R Soc Lond B Biol Sci. 351:1996;441-448.
71. Woolf C.J., Allchorne A., Safieh-Garabedian B., Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumor necrosis factor-alpha. Br J Pharmacol. 121:1997;417-424.
72. Zhang Y., Pilon G., Marette A., Baracos V.E. Cytokines and endotoxin induce cytokine receptors in skeletal muscle. Am J Physiol Endocrinol Metab. 279:2000;E196-E205.
73. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.